Clinical Trial Update: Effect of Sublingual Fentanyl on Breathlessness in COPD [Phase 2, Phase 3]

View source ↗

Summary

A Phase 2/Phase 3 randomized trial evaluating sublingual fentanyl for relief of breathlessness in chronic obstructive pulmonary disease was terminated, and no r…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Obstructive Pulmonary Disease

Drugs mentioned

• sublingual fentanyl (fentanyl)

Snippet

Sponsor: McGill University Health Centre/Research Institute of the McGill University Health Centre | Conditions: Copd | Phase 2, Phase 3 | Status: TERMINATED